# Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis

> **NCT01072773** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 2 (actual)

## Conditions studied

- Primary Systemic Amyloidosis

## Interventions

- **DRUG:** bortezomib
- **DRUG:** cyclophosphamide
- **DRUG:** dexamethasone

## Key facts

- **NCT ID:** NCT01072773
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2011-03
- **Final completion:** 2012-06
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2014-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01072773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01072773, "Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01072773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*